Scientists have discovered what they say is a powerful pain reliever that acts on a previously unknown pain pathway.
The synthetic compound, known as UKH-1114, is as effective at relieving neuropathic pain in injured mice as a drug widely used for pain relief called gabapentin, but it works at a much lower dose, with longer duration of action.
Neuropathic pain, or chronic pain, arises from damage to nerves in the central nervous system. Among other things, it can result from chemotherapy, diabetes, and injuries to the brain or spinal cord.
If the researchers can demonstrate that the drug is safe, effective, and non-addictive in humans—a process that typically takes years—the discovery could be instrumental in addressing one of today’s biggest public health challenges: the opioid abuse epidemic.
Nearly a third of Americans suffer from chronic pain, yet the most effective pain relievers—opioids—are addictive and often require increased dosing to maintain efficacy.
According to the National Institute on Drug Abuse, about 2 million people in the US suffer from addiction to prescription opioid pain relievers.
Alternatives to opioids have their own drawbacks—for example, gabapentin (sold as Neurontin) can cause cognitive impairment in certain individuals.
“This opens the door to having a new treatment for neuropathic pain that is not an opioid,” says study co-leader Stephen Martin, a professor and chair in chemistry at the University of Texas at Austin. “And that has huge implications.”
The pain drug they found binds to a receptor on cells throughout the central nervous system called the sigma 2 receptor. Although it was discovered 25 years ago, scientists still did not know what sigma 2 did until now.
Theodore Price, associate professor of neuroscience, tested UKH-1114 on mice with nerve damage and found that it alleviated pain as well as gabapentin did, but at a much lower dose (one-sixth as much) and was effective much longer (lasting for a couple of days, compared with 4 to 6 hours).
This research is the first to demonstrate that the sigma 2 receptor may be a target for treating neuropathic pain.
Results appear in ACS Chemical Neuroscience. An earlier paper, published in the Proceedings of the National Academy of Sciences, describes the molecular cloning and identification of the sigma 2 receptor.
The researchers have filed patent applications on the new compound.
Much work remains to be done before UKH-1114 can enter the market. More studies are needed to demonstrate safety, efficacy, and oral bioavailability.
In the meantime, the scientists are working to understand, on a fundamental level, how activating the sigma 2 receptor relieves neuropathic pain.
“We started out just working on fundamental chemistry in the lab,” says study co-leader James Sahn, a research scientist in the UT Austin chemistry department.
“But now we see the possibility that our discoveries could improve the quality of people’s lives. That is very satisfying.”